There is no official cure for mesothelioma. Even with the most aggressive treatment available today, the cancer carries an average life expectancy of 12 to 21 months after diagnosis. But “no cure” does not mean “no hope.” A growing number of patients are reaching complete remission, where no detectable disease remains in the body, and newer treatments like immunotherapy are producing durable responses that last years in some cases.
What Remission Means for Mesothelioma
Oncologists distinguish between three treatment outcomes. Complete remission means scans and tests show no remaining cancer. Partial remission means tumors have shrunk but haven’t disappeared entirely. Stable disease means the cancer has stopped growing but hasn’t receded. Any of these can follow treatment, and each changes the outlook differently.
Complete remission is possible, but doctors still avoid using the word “cure” because mesothelioma has a high recurrence rate. Cancer cells can remain undetectable for months or years before growing again. That said, some patients do stay in remission for five years or longer, particularly those diagnosed early with the most treatable cell type.
How Cell Type and Stage Shape the Outlook
Mesothelioma tumors come in three main cell types, and this single factor has an outsized effect on prognosis. Epithelioid mesothelioma, the most common form, carries a median survival of about 14.4 months. Biphasic (a mix of cell types) drops to 9.5 months, and sarcomatoid, the most aggressive form, averages just 5.3 months.
Stage at diagnosis matters just as much. According to American Cancer Society data drawn from patients diagnosed between 2015 and 2021, the five-year relative survival rate for localized pleural mesothelioma (cancer still confined to where it started) is 23%. For regional disease that has spread to nearby tissues, that drops to 15%. For distant disease, it falls to 11%. These numbers reflect all treatment types combined, so individual outcomes can be significantly better or worse depending on the treatment plan and overall health.
Surgery: Two Approaches, Different Tradeoffs
For patients whose cancer hasn’t spread too far and who are healthy enough to tolerate a major operation, surgery offers the best chance at long-term survival. Two primary procedures exist for pleural mesothelioma, which forms in the lining of the lungs.
Pleurectomy/decortication (P/D) removes the diseased lining around the lung but spares the lung itself. Extrapleural pneumonectomy (EPP) removes the lining, the entire lung on the affected side, and sometimes part of the diaphragm. In a matched comparison of the two, P/D patients had a median survival of 22 months versus 15 months for EPP. The perioperative mortality rate, meaning deaths during or shortly after surgery, was 0% for P/D compared to 11% for EPP. Because P/D preserves the lung, it also comes with fewer heart and lung complications during recovery.
Neither surgery eliminates the cancer on its own. The best results come from combining surgery with chemotherapy and sometimes radiation, an approach called multimodal therapy. Among all mesothelioma patients in one large study, those receiving multimodal treatment reached a median survival of 27 months. For patients with early-stage epithelioid disease specifically, that number climbed to 37 months.
Immunotherapy Is Changing Survival Patterns
The most significant treatment advance in recent years is a combination immunotherapy now approved as a first-line option in the United States and European Union. This regimen uses two drugs that help the immune system recognize and attack mesothelioma cells. A landmark trial called CheckMate 743 followed patients for five years and found that immunotherapy more than doubled the rate of long-term survival compared to standard chemotherapy: 14% of immunotherapy patients were alive at five years versus 6% on chemotherapy.
What makes this result particularly striking is the durability. Among patients whose tumors responded to immunotherapy, 17% still had ongoing responses at the five-year mark. Among chemotherapy responders, that number was 0%. In other words, when immunotherapy works, it can keep working for years. The initial tumor shrinkage rates were similar between the two groups (39% for immunotherapy, 44% for chemotherapy), but immunotherapy responses lasted far longer.
Peritoneal Mesothelioma Has a Different Trajectory
Mesothelioma that develops in the abdominal lining rather than the lungs, called peritoneal mesothelioma, actually has a better prognosis when treated aggressively. The standard approach combines surgery to remove visible tumors with a technique that bathes the abdominal cavity in heated chemotherapy during the operation. Patients who received this combined treatment reached a median survival of about 44.6 months, nearly four years. Those who could not undergo surgery and received chemotherapy alone survived a median of 11 to 13 months.
A Device That Uses Electrical Fields
An FDA-approved wearable device offers another option for pleural mesothelioma. It delivers low-intensity alternating electrical fields through pads placed on the chest. These fields interfere with cancer cell division, causing the cells to die while leaving normal cells largely unaffected. In a clinical study, patients using the device alongside chemotherapy achieved a median survival of 18.2 months, with 62% alive at one year and 42% alive at two years. The device is worn for most of the day and allows patients to continue their normal activities during treatment.
Why Early Detection Is So Difficult
One reason mesothelioma remains so hard to treat is that it’s rarely caught early. Symptoms like chest pain, shortness of breath, and fluid buildup don’t usually appear until the disease is advanced, often 20 to 50 years after asbestos exposure. By the time most people are diagnosed, the cancer has already spread beyond the point where surgery can remove it completely.
Blood-based biomarkers are being used to help identify the disease sooner, particularly in people with known asbestos exposure. One protein marker detects mesothelioma with a sensitivity of 60 to 90% and a specificity of 80 to 85%, meaning it correctly identifies most cases while producing relatively few false alarms. A newer marker called fibulin-3 has shown even stronger accuracy in studies, with sensitivity of 96.7% and specificity of 95.5%. These tests are most useful for monitoring high-risk individuals rather than screening the general population, since the cancer is rare enough that false positives would be a significant problem in widespread screening.
Experimental Treatments in Clinical Trials
Several experimental approaches are in early testing. One of the most watched is a type of engineered immune cell therapy that reprograms a patient’s own immune cells to target mesothelin, a protein found on the surface of mesothelioma tumors. Phase 1 trials are underway, and while no results have been published yet, the approach has shown promise in other cancers that share this protein target. Enrolling in a clinical trial can provide access to these therapies before they reach wider approval, and many mesothelioma specialists consider trial participation a standard part of treatment planning rather than a last resort.
The honest answer to “is there a cure?” is that no treatment today guarantees the cancer won’t come back. But the gap between “no cure” and “no options” is wide and growing. Patients diagnosed with early-stage epithelioid disease who receive multimodal treatment can survive three years or longer. Immunotherapy is producing five-year survivors where chemotherapy alone could not. And for peritoneal mesothelioma, aggressive surgical treatment is pushing median survival past the four-year mark.